ASH 2018 | Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
In this interview, Saar Gill, MD, PhD, from the University of Pennsylvania, Philadelphia, PA., discusses a pilot trial (NCT03331198) of autologous anti-CD19 CAR T-cell therapy in adults with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were not in complete response despite at least 6 months treatment with ibrutinib. Dr Gill discusses the safety and efficacy data, including an iwCLL complete remission rate of 43% and a bone marrow remission rate of 94%, which compares favorably to prior studies in patients with progressive CLL. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up